• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • PROs
    • Menopause Rating Scale
      • Menopause Rating Scale (MRS) – Languages
    • Aging Male Symptoms Scale
      • AMS – properties as an outcome measure
      • AMS – properties as a screening tool
    • Quality of Sexual Function Scale
      • Quality of Sexual Function Scale
    • Short Term Hormone Effect Scale
      • Short Term Hormone Effect Scale
    • Research team
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Publications

Heinemann Klaas, Dinger Jürgen, Baseline risk factors for cardiovascular events: differences between the USA and Russia in a study population of combined oral contraceptives Pharmacoepidemiology and Drug Safety. 2014; Sep; 23(S1): 1-497. 10.1002/pds.3701.
Rabe T (DGGEF) und Albring C(BVF) zusammen mit dem Arbeitskreis "Thrombophilie und Kontrazeption" , Luxembourg B, Ludwig M, Dinger Jürgen, Bauersachs R, Rott H, Koenig K, Merkle E, Mueck A O, Merki G, Egarter C, Sicherheit hormonaler Kontrazeptiva: Diane 35 und deren Generika.. Frauenarzt 54. 2013; Nr.4.
Dinger Jürgen, Nitschmann S, Kardiovaskuläre Auswirkungen hormoneller Kontrazeption Internist. 2013; 54:1520-1522. doi:10.1007/s00108-013-3394-5.
Bardenheuer Kristina, Dinger Jürgen, Do Minh Thai, Venous thromboemolism in users of a 24-day regimen of a combined oral contraceptive compare to conventional 21-day regimens: final results from the INAS-OC study. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Heinemann Klaas, Dinger Jürgen, Bardenheuer Kristina, The safety of oral contraceptives in adolescents. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Dinger Jürgen, Heinemann Klaas, Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstetrics & Gynecology. 2013; 122(4): 800 - 808. 10.1097/AOG.0b013e3182a5ec6b.
Download PDF: Cardiovascular_Risk_Associated_With_the_Use_of_an.11.pdf
Heinemann Klaas, Ectopic pregnancies under IUD use: interim results from the EURAS-IUD study Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Heinemann Klaas, Breastfeeding as as risk factor for uterine preforation during IUD insertion: interim results from the ERUAS-IUD study Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Dinger Jürgen, Heinemann Klaas, Transatlantic active surveillance of cardiovascular safety (TASC) of an Etonogestrel/Ethinylestradiol-containing vaginal ring. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Dennerstein L, Lehert P, Heinemann Klaas, Epidemiology of premenstrual symptoms and disorders. Menopause International. 2012; Jun;18(2):48-51.
Heinemann Klaas, Assmann Anita, Dinger Jürgen, The safety of oral hormone replacement therapy: final results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 365. DOI 10.1002.
Bardenheuer Kristina, Dinger Jürgen, VTE risk in users of combined oral contraceptives: impact of a 24-Day regimen containing drospirenone. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 361. DOI 10.1002.
  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Interim pages omitted …
  • Page 22
  • Go to Next Page »

sidebar

Search our Publications

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2025 ZEG Berlin

Impressum

Website by Laura Yeffeth.